Vivo Bio Tech Ltd.

As of June 30, 2026, Vivo Bio Tech Ltd. carries a market capitalization of 530.13M, placing it among publicly traded companies globally. Its enterprise value stands at 530.13M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Vivo Bio Tech Ltd. has 22.19M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Vivo Bio Tech Ltd. trades at an EV/EBITDA multiple of 2.60 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.96 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 530.13M versus a market cap of 530.13M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 2.17M in revenue per employee across its workforce of 253.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Vivo Bio Tech Ltd. recorded 65.27M in income tax expense. That works out to an effective tax rate of 177.91, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 36.69M, leaving -28.58M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Vivo Bio Tech Ltd.'s stock has declined approximately 65.58% over the past 52 weeks. The 50-day moving average sits at 17.06, while the 200-day moving average is 23.81.

Over the twelve months ended June 30, 2026, Vivo Bio Tech Ltd. generated 551.03M in revenue and converted that into -28.58M in net income, yielding earnings per share of -1.34. EBITDA reached 204.08M, while operating income came in at 94.98M.

Over the twelve months ended June 30, 2026, Vivo Bio Tech Ltd. posted a gross margin of 84.62, reflecting its pricing power and cost economics. The operating margin of 17.24 and net profit margin of -5.19 provide insight into operational efficiency.

Vivo Bio Tech Ltd.'s most recent stock split took place on October 7, 2005 with a 10:1 split ratio.